2015³âµµ ´ëÇÑÀ̽ÄÇÐȸ Á¦7Â÷ À©ÅͽÉÆ÷Áö¾ö


ÀϽÃ: 2015³â 2¿ù 6ÀÏ(±Ý)-7ÀÏ(Åä)
Àå¼Ò: ±º»ê º£½ºÆ®¿þ½ºÅÏÈ£ÅÚ


2¿ù 6ÀÏ (±Ý) 
08:30-08:50 µî·Ï
08:50-09:00 °³È¸½Ä
09:00-10:40 Session I : Practical application of Basic research
10:40-11:00 Coffee Break
11:00-12:20 Session II: Investigational New drug
12:20-13:30 Luncheon Symposium
13:30-14:10 Special lecture
14:10~14:30 Coffee Break
14:30~16:30 Session III : Á¶Á÷±âÁõ°ü·Ã ü°è º¯È­¿¡ °üÇÑ °ü¸® ¹× Çù·Â ¹æ¾È¿¡ °üÇÑ ÅäÀÇ
16:30~18:00 Poster session
2¿ù 7ÀÏ (Åä)
08:00-10:00 Donor evaluation and Selection



2¿ù 6ÀÏ (±Ý)
08:30-08:50 µî·Ï  
08:50-09:00 °³È¸½Ä ȸÀå: ±èµ¿±¸(°¡Å縯ÀÇ´ë)
09:00-10:40 Session I : Practical application of Basic research ÁÂÀå: ±èµ¿±¸(°¡Å縯ÀÇ´ë), ¾È±Ô¸®(¼­¿ïÀÇ´ë)
09:00-09:20 Translational Medicine, Changing paradigm ¾È±Ô¸®(¼­¿ïÀÇ´ë)
09:20-10:00 ±âÃÊ¿¬±¸¼º°úÀÇ ÇöÀåÀû¿ë ÃËÁøÀ» À§ÇÑ Áß°³¿¬±¸ ±èº´¼ö(°í·ÁÀÇ´ë)
10:00-10:40 How to survive a Korea-born biotech in the Red Oceans of the World? À±º´¼ö(¿À½ºÆ¼¿À ´º·ÎÁ¨)
10:40-11:00 Coffee Break
11:00-12:20 Session II: Investigational New drug ÁÂÀå: ¹Ú¼º±¤(ÀüºÏÀÇ´ë), ±è¼ºÁÖ(¼º±Õ°üÀÇ´ë)
11:00-11:40 JL1, A Novel Therapeutic Target in Acute Leukemia Á¤°æõ(¼­¿ïÀÇ´ë)
11:40-12:20 Developing a new drug for selective depletion of alloreactive effector T cells ¼­¼ö±æ(ÀÎÁ¦ÀÇ´ë)
12:20-13:30 Luncheon Symposium(¾Æ½ºÅÚ¶ó½º)
ÁÂÀå: Á¶Àç¿ø(¼º±Õ°üÀÇ´ë), ÃÖµ¿¶ô(°¡Å縯ÀÇ´ë)
SMART study :
A Phase IV, Single center, Open-label, Randomized Study to evaluate the Safety and Efficacy of a Tacrolimus twice daily, PROGRAF® versus a Tacrolimus Modified Release, ADVAGRAF®, in stable Liver transplant recipients taking Tacrolimus twice daily.
±èÁ¾¸¸(¼º±Õ°üÀÇ´ë)
13:30-14:10 Special lecture ÁÂÀå: À̼®±¸(¼º±Õ°üÀÇ´ë), ±è¼øÀÏ(¿¬¼¼ÀÇ´ë)
13:30-14:10 Current issues in liver transplantation Yasuhiro Ogura(Nagoya University Hospital)
14:10-14:30 Coffee Break
14:30-16:30 Session III : Á¶Á÷±âÁõ°ü·Ã ü°è º¯È­¿¡ °üÇÑ °ü¸® ¹× Çù·Â ¹æ¾È¿¡ °üÇÑ ÅäÀÇ ÁÂÀå: Á¶¿øÇö(°è¸íÀÇ´ë), ±èÇü¼÷(¼­¿ï¼º¸ðº´¿ø)
14:30-15:00 ÀÎüÁ¶Á÷ ±âÁõ/±¸µæü°è Á¤¾ç±¹(°¡Å縯ÀÇ´ë)
15:00-15:30 Á¶Á÷±âÁõÁö¿ø±â°ü ÃÖ±Ô¼º(¼º±Õ°üÀÇ´ë)
15:30-16:00 Á¶Á÷±âÁõ°ü·Ã ÄÚµð³×ÀÌÅÍÀÇ ¿ªÇÒ ±èÀοÁ(¼­¿ï¾Æ»êº´¿ø)
16:00-16:30 Çѱ¹Àå±â±âÁõ¿øÀÇ ¿ªÇÒ °­ÇöÁø(Çѱ¹Àå±â±âÁõ¿ø)
16:30-18:00 Poster session ÁÂÀå: Á¶È«·¡(¿ï»êÀÇ´ë), °øÁø¹Î(BHSÇѼ­º´¿ø)



2¿ù 7ÀÏ (Åä)
08:00-10:00 Donor evaluation and Selection  
08:00-10:00 Room A : Kidney Donor Evaluation and Selection Criteria ÁÂÀå: Á¶¹éȯ(ÀüºÏÀÇ´ë), ±èÀ¯¼±(¿¬¼¼ÀÇ´ë)
08:00-08:30 Current improvement of deceased donor management ¹ÚÀç¹ü(¼º±Õ°üÀÇ´ë)
08:30-09:00 Selection criteria of marginal donors and their recipients ¿ÀÁؼ®(ºÀ»ýº´¿ø)
09:00-09:30 Dual kidney transplantation ±èÇüÅÂ(°è¸íÀÇ´ë)
09:30-10:00 Panel discussion  
08:00-10:00 Room B : Living Liver Donor Evaluation and Selection Criteria ÁÂÀå: ¼­°æ¼®(¼­¿ïÀÇ´ë), ³ª¾ç¿ø(¿ï»êÀÇ´ë)
08:00-08:15 Living Liver Donor Evaluation and Selection Criteria:
Right Liver Graft- Remnant Volume over 30%
À̳²ÁØ(¼­¿ïÀÇ´ë)
08:15-08:30 Right lobe graft-Remnant volume less than 30% À̽´ö(±¹¸³¾Ï¼¾ÅÍ)
08:30-09:00 Paradigm shift in the adult living donor liver transplantation between the left liver and the right liver Yasuhiro Ogura(Nagoya University Hospital)
09:00-09:30 Living Liver Donor Evaluation and Selection Criteria:
Right Posterior Sector Graft
±èºÀ¿Ï(¾ÆÁÖÀÇ´ë)
09:30-10:00 ABO incompatable liver transplantation ¼Û±â¿ø(¿ï»êÀÇ´ë)